Frontlight ResearchEarly access
TerminatedPhase 2
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Key facts
- Who runs it
- Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 25 people enrolled
- Started
- 21 Mar 2022
- Ended
- 21 Jul 2025
- Type of study
- Interventional
- Treatments tested
- Deferoxamine Plus Chemotherapy
- Record updated
- 22 July 2025
- Why it stopped
- Difficulty accruing subjects the study accrual was closed.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria
- Fail second-line or above anti-tumor treatment
- Evaluation is stable disease with a trend of progression
- Minimum life expectancy 16 weeks
- Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis
- ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks
- Normal organ function
- Has signed a Patient Informed Consent Form
Who cannot take part
- With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment
- Inability or unwillingness to comply with study procedures, including inability to take regular oral medication
- Patients with severe liver and kidney insufficiency
- Deferoxamine Ingredients allergy
- Eastern Cooperative Oncology Group (ECOG) score of ≥ 2
- Researchers consider it is not suitable for participation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
The group in the trial
- Treatment armTreatment being tested
Deferoxamine:50mg/kg+500ml normal saline (NS) plus chemotherapy
Treatment: Deferoxamine Plus Chemotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial
- Record updated
- 22 July 2025